On 27 January UnitedHealth told investors 2026 revenue would exceed $439.0 billion, and said in the same paragraph what that meant: "a 2% year-over-year decline reflecting planned right-sizing across the enterprise." Against the $447.6 billion the company had just reported for 2025, it was guiding its own top line down, on purpose.
Six months in, the top line is going the other way. First-half revenue was $223.75 billion, up 1.2% on the $221.19 billion of the first half of 2025 — 51.0% of the full-year floor, booked in half the year. For 2026 to land exactly on $439.0 billion, the second half would have to print $215.2 billion: 4.9% below the second half of 2025 and 3.8% below the half that just finished. Nothing disclosed supports a step-down that size. Annualise the first half and you get $447.5 billion. The four most recently reported quarters sum to $450.1 billion, though that window straddles two calendar years and is not the like-for-like comparison — the first-half figure is.
Call the over-run $8 billion, then. The interesting part is that $8 billion of UnitedHealth revenue is worth almost nothing.
What the over-run is worth, and what actually moved the guide
UnitedHealth's own January outlook put full-year operating margin at about 5.5%. Eight and a half billion dollars of revenue at 5.5% is $468 million of operating earnings; at the ~18.5% tax rate the company now guides to, across 906 million diluted shares, that is about $0.42 a share. Run the same arithmetic on our model's slightly more conservative full-year figure and it is $0.37. Call it forty cents. That arithmetic is ours, on the company's own guided ratios.
Now the raise. On 16 July UnitedHealth lifted its adjusted earnings outlook from a floor of more than $17.75 to a range of $19.50–$20.00 — $2.00 above the floor at the midpoint — and raised the operating-earnings floor from more than $24.0 billion to more than $25.45 billion, an increase of $1.45 billion. Forty cents of that $2.00 is the revenue over-run. The other $1.60 is not.
The rest is the medical care ratio, which is the only line that matters at this company's multiple. January guided a full-year ratio of 88.8% ± 50 basis points; July guided 88.1% ± 25 basis points — 70 basis points better and with the band halved. Seventy basis points on UnitedHealth's roughly $349 billion of annualised premium revenue is about $2.4 billion pre-tax, more than the entire raise on its own. It nets down to $1.45 billion because the operating cost ratio moved the other way: 12.7% in the June quarter against 12.3% a year earlier, on what the company calls targeted investment in technology, care delivery and community support.
And here is the sentence that matters for an insurer, where a revenue beat is usually bad news wearing a good headline. UnitedHealth's first-half revenue rose $2.56 billion. Its first-half medical costs fell $3.15 billion. The top line did not go up because claims did.
Where the revenue came from
The composition of that $2.56 billion is the whole mechanism, and it is on the face of the income statement:
- Premiums: $174.52 billion, against $174.44 billion. Up $78 million on a $174 billion base — dead flat.
- Services: $19.80 billion, up 9.9% — $1.79 billion, or 70% of all the growth.
- Products: $27.09 billion, up 1.8%; investment and other income $2.35 billion, up 10.0%.
- Medical costs: $148.85 billion, down 2.1% — a $3.15 billion reduction against flat premium revenue. The half's medical care ratio was 85.3%, against 87.1% a year earlier.
- And the membership behind it is coming down roughly as planned. UnitedHealthcare served 48.5 million people at 30 June, down 525,000 in the quarter; Medicare Advantage has contracted by 965,000 since year-end. January guided total medical membership down 2.3 to 2.8 million for the year.
That is why the floor was set where it was, and why it is being cleared. The $439.0 billion was the arithmetic of a subtraction plan — a headcount the company intended to shed, priced at something like the current rate. Two things have happened that the plan did not carry. The attrition is shallower in the one place it costs the most revenue per head: on the July call management said it now expects full-year Medicare Advantage enrolment to fall by approximately 1.1 million, against the 1.3 to 1.4 million written into the January outlook. And revenue per remaining member rose enough to hold premiums exactly flat while the members left. Add consolidated services revenue growing 9.9% and the floor is cleared without a single additional insured life.
A guide built by counting members out is low by construction if price per member holds. That is not a beat in any sense management would recognise, which is presumably why the July guidance table updated operating earnings, net earnings, the medical care ratio, the tax rate, cash flow, the buyback and both earnings ranges — and carried no revenue row at all. The $439.0 billion floor was not reaffirmed in July. It was simply left alone. The summary card above lays the two curves side by side.
What it does to the model
Almost nothing, and the size of the nothing is the point. Our UnitedHealth model, built on the June quarter, already lands full-year 2026 revenue at $446.4 billion — above the $439.0 billion floor, and above every per-segment floor the January release published: UnitedHealthcare $342.7 billion against more than $335.0 billion, Optum Health $92.4 billion against more than $91.0 billion, Optum Insight $21.4 billion against more than $21.0 billion, Optum Rx $152.8 billion against more than $150.5 billion. Those are our projections, not company figures. The model's base case is $403.52 a share against the $398.76 price it was built on at 27 August — a 1.2% gap. A company clearing its revenue floor by $8 billion produces no valuation event here, because at nine-tenths of a year's revenue in enterprise value the equity is a margin instrument: ten basis points of group operating margin is about forty cents of adjusted earnings per share, the same forty cents the entire over-run is worth.
The February piece had the right subject and the wrong headline
We wrote this company up in February under the headline "UnitedHealth's First Revenue Decline in Decades. The $439B Guidance Problem." The body was a margin argument — the 92.4% fourth-quarter medical care ratio, the near-flat proposed 2027 Medicare Advantage rate update, the DOJ overhang — but the headline sold the revenue line, and the revenue line is the part that has not happened. That piece also read the $17.75 adjusted floor as implying "$4-5 per quarter"; on the same adjusted basis the first half of 2026 came in at $13.61, against the $8 to $10 that arithmetic implies, and the year is now guided to $19.50–$20.00. Of the two readings it offered — sandbagging, or a new and lower baseline — the sandbagging one was right.
What October settles
- The second-half medical care ratio. The 88.1% full-year guide implies a second half near 90.9% if premiums run at twice the first half — which is roughly where the second half of 2025 landed (91.1%). The guide embeds no further year-on-year improvement after June. All of the full-year gain is already banked.
- How much of June was development. The quarter's 86.7% ratio included $860 million of net favourable prior-period reserve development, most of it on 2026 dates of service, and days claims payable fell to 47.0 from 48.6 in March. The company calls that normal seasonality.
- Commercial cost trend. On the July call, management said that within commercial offerings "we are not yet seeing evidence of cost trend moderation. In fact, it is the opposite, with medical cost trends modestly above 11% level we previously saw." The consolidated ratio hides that; only the call splits it.
- Whether a revenue number reappears. If the third-quarter release prints a new full-year revenue outlook, the January floor stops being the comparison and this whole gap closes on paper.
The $439.0 billion revenue floor, the 2% decline it implies, the per-segment floors, the 88.8% ± 50bp medical care ratio and the $17.75 adjusted earnings floor are from UnitedHealth's 27 January 2026 full-year results and 2026 outlook release. The first-half income statement, the June-quarter figures, the raised 16 July guidance and the absence of a revenue row in it are from the second-quarter release, captured in our June-quarter coverage. The Medicare Advantage revision and the commercial cost-trend quotation are from the July earnings call, transcribed by a third party and checked against the captured text. Every ratio, annualisation, per-share conversion and the $215.2 billion second-half figure are ours, derived from those disclosed inputs; the full-year segment and consolidated revenue projections and the $403.52 base case are our model's assumptions as published, not company guidance, against the $398.76 price it was built on at 27 August, which is not today's quote.
